Valneva SE (VALN)
NASDAQ: VALN · Real-Time Price · USD
7.18
-0.17 (-2.31%)
Aug 1, 2025, 4:00 PM - Market closed
Valneva SE Employees
Valneva SE had 713 employees as of December 31, 2024. The number of employees increased by 37 or 5.47% compared to the previous year.
Employees
713
Change (1Y)
37
Growth (1Y)
5.47%
Revenue / Employee
$282,047
Profits / Employee
-$121,861
Market Cap
612.63M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 713 | 37 | 5.47% |
Dec 31, 2023 | 676 | -43 | -5.98% |
Dec 31, 2022 | 719 | -43 | -5.64% |
Dec 31, 2021 | 762 | 262 | 52.40% |
Dec 31, 2020 | 500 | -21 | -4.03% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
VALN News
- 5 days ago - AGC Biologics' Heidelberg Site Supplies Drug Substance for Phase II Studies of Valneva's Tetravalent Shigella Vaccine Candidate - Business Wire
- 23 days ago - Valneva Announces Lifting of European Medicines Agency's Temporary Restriction on Use of Chikungunya Vaccine IXCHIQ® in Elderly - GlobeNewsWire
- 23 days ago - Europe lifts restriction on Valneva's chikungunya vaccine for elderly adults - Reuters
- 5 weeks ago - Valneva Announces Exclusive Vaccine Marketing and Distribution Agreement for Germany with CSL Seqirus - GlobeNewsWire
- 5 weeks ago - Valneva Announces Successful Outcome of its Annual General Meeting, Confirms FY 2025 guidance - GlobeNewsWire
- 7 weeks ago - UK's MHRA suspends Valneva's chikungunya vaccine for elderly - Reuters
- 2 months ago - Valneva Reports Positive Six-Month Antibody Persistence and Safety Phase 2 Results in Children for its Single-Shot Chikungunya Vaccine IXCHIQ® - GlobeNewsWire
- 2 months ago - Valneva Announces Availability of Documentation for its Combined Shareholder Meeting and Provides Corporate Update - GlobeNewsWire